Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
6.90
+0.67 (10.75%)
At close: Mar 12, 2026, 4:00 PM EDT
6.78
-0.12 (-1.74%)
After-hours: Mar 12, 2026, 4:19 PM EDT

Atara Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
151.93128.948.5763.5720.34-
Revenue Growth (YoY)
51.27%1404.02%-86.52%212.55%--
Cost of Revenue
27.921.018.89---
Gross Profit
124.03107.93-0.3163.5720.34-
Selling, General & Admin
31.4239.8950.9171.5578.864.4
Research & Development
66.39151.48224.79272.53282244.65
Total Operating Expenses
97.81191.37275.69344.09360.8309.05
Operating Income
26.22-83.44-276.01-280.51-340.46-309.05
Interest Income
1.182.115.433.06--
Interest Expense
-3.92-4.62-5.29-0.37--
Other Non-Operating Income (Expense)
-0.070.53-0.2549.54--
Total Non-Operating Income (Expense)
-3.32-1.98-0.1152.220.734.89
Pretax Income
23.41-85.42-276.11-228.29-340.1-306.61
Provision for Income Taxes
0.01-0.010.020.010.050.02
Net Income
23.4-85.4-276.13-228.3-340.14-306.62
Net Income to Common
23.4-85.4-276.13-228.3-340.14-306.62
Shares Outstanding (Basic)
1274443
Shares Outstanding (Diluted)
1274443
Shares Change (YoY)
101.28%76.77%3.83%8.88%26.63%44.17%
EPS (Basic)
2.22-11.41-65.19-56.00-90.75-103.75
EPS (Diluted)
2.18-11.41-65.19-56.00-90.75-103.75
Free Cash Flow
-69.8-68.96-194.2-274.62-231.1-185.27
Free Cash Flow Per Share
-5.89-9.21-45.85-67.32-61.68-62.61
Gross Margin
14.81%83.71%-3.65%100.00%100.00%-
Operating Margin
80.06%-64.71%-3219.48%-441.25%-1673.85%-
Profit Margin
71.45%-66.23%-3220.88%-359.12%-1672.28%-
FCF Margin
-213.12%-53.48%-2265.25%-431.98%-1136.19%-
EBITDA
29.39-78.39-271.18-274.86-331.12-300.72
EBITDA Margin
89.73%-60.79%-3163.15%-432.35%-1627.91%-
EBIT
26.22-83.44-276.01-280.51-340.46-309.05
EBIT Margin
80.06%-64.71%-3219.48%-441.25%-1673.85%-
Effective Tax Rate
0.05%0.01%-0.01%-0.01%-0.01%-0.00%
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q